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over the last 10 years mainly due to the development of 
eﬀective oral antiviral agents (nucleoside/nucleotide 
analogs (NUCs)) (3). NUCs used in hepatitis B virus (HBV) 
therapy belong to the following 3 classes:
L-nucleosides: lamivudine (LAM), telbivudine (LdT), 
and emtricitabine; Deoxyguanosine analogs: entecavir 
(ETV); Acyclic nucleoside phosphonates: adefovir dipiv-
oxil (ADV) and tenofovir disoproxil fumarate (TDF). 
Currently, LAM, ADV, ETV, TDF, and LdT have been li-
1. Background
Treatment for chronic hepatitis B (CHB) has improved 
Background: Treatment for chronic hepatitis B (CHB) has improved over the last 10 years 
mainly due to the development of eﬀective oral antiviral agents [nucleoside/nucleotide 
analogs (NUCs)].
Objectives: The aim of the present study is to identify the frequency and major patterns of 
resistance to the hepatitis B virus (HBV) in a Turkish population of CHB patients treated 
with NUCs using add-on and switch therapy strategies.
Patients and Methods: The investigation involved a total of 194 patients (88 were treated 
using add-on therapy, and 106 were treated using switch therapy). We analyzed the HBV 
polymerase gene by ampliﬁcation and direct sequencing procedures.
Results:  Primary drug-resistance mutations were detected in 84 patients (43%; 42 in 
add-on therapy, and 42 in switch therapy) taking lamivudine (LAM), 10 patients (5%; 6 
in add-on therapy, and 4 in switch therapy) taking entecavir (ETV), and 16 patients (8%; 
8 in add-on therapy, and 8 in switch therapy) taking adefovir (ADV). The most common 
LAM and ETV resistance mutations were rtM204I/V, rtL180M and rtT184A/I/S, respectively, 
while rtA181T/V and rtN236T substitutions were the most frequently observed ADV resist-
ance mutations.
Conclusions: Patients with CHB who developed NUC resistance were managed using 2 dif-
ferent rescue strategies. The frequency and mutation pattern of resistance were similar 
in patients treated with add-on and switch strategies. These ﬁndings may be helpful in 
the management of rescue strategies in LAM-resistant patients.
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censed for the treatment of CHB (3, 4).
Antiviral drug resistance now poses a major problem 
for the management of patients with CHB. Long-term 
therapy with NUCs, in particular, is associated with an 
increased risk of development of drug resistance (5, 6). 
In theory, resistance may be prevented if a suﬃciently 
potent antiviral drug, or a combination of NUCs, is used 
such that viral replication and the ongoing selection of 
HBV quasispecies are prevented (5). Mutations selected 
by treatment with NUCs can be split into 2 groups: those 
that cause resistances, sometimes leading to decreased 
viral ﬁtness, and compensatory mutations, which par-
tially or fully restore viral ﬁtness (7). The main muta-
tion associated with LAM and L-nucleoside resistances 
is rtM204I/V, a mutation that occurs within the YMDD 
motif of the reverse transcriptase (rt) region of the poly-
merase (5). Nine major mutation patterns associated 
with LAM resistance have been reported:     (i) rtM204I/V + 
rtL180M; (ii) rtM204I; (iii) rtV173L + rtL180M + rtM204V; 
(iv) rtL80I + rtM204I; (v) rtQ215S + rtM204I/V ± rtL180M; 
(vi) rt169T + rtV173L + rtL180M + rtM204V; (vii) rtA181T; 
(viii) rtT184S + rtM204I/V ± rtL180M, and (ix) rtM204S + 
rtL180M. Some of these mutations can act as compensa-
tory mutations, such as rtL80I/V and rtV173L (5). LdT se-
lects for mutations in the YMDD motif, and to date, only 
rtM204I (but not rtM204V) has been observed (3, 8). Two 
patterns of ETV resistance have been characterized, and 
they include the LAM-resistance mutation rtM204I/V plus 
an additional mutation of either rtT184G + rtS202I/C or 
rtM250V + rtI169T (5, 9). Similarly, the mechanism medi-
ating ADV resistance has been characterized, with major 
resistance mutations located at rtN236T and/or rtA181T/V 
(6, 10), and a number of other mutations found in 3 clus-
ters within the rt region of the HBV polymerase (11). In 
contrast, reports have shown that the TDF treatment 
induces little selection for viral resistance. For example, 
studies demonstrated that the rtA194T mutation in the 
HBV genome led to a decrease in HBV replication capac-
ity with TDF treatment; however, additional and more 
long-term data investigating the eﬀects of TDF treatment 
on HBV resistance are needed (3, 7). The complex patterns 
of mutations that can accumulate over time may aﬀect 
the eﬃcacy of subsequent treatments, suggesting that 
the identiﬁcation of mutations will quickly become an 
important component in the management of patients 
with CHB (12).
NUC-resistant HBV variants can commonly be detected 
by direct sequencing of HBV DNA (13). Sequence analysis 
is considered to be the gold standard for characterizing 
HBV DNA isolates (14). However, the sensitivity of direct 
sequencing for the detection of minor variant popula-
tions is poor, and in general, these methods will detect 
mixtures of variant populations (15, 16). Sequencing a 
large number of clinical samples is time consuming, but 
it is suitable for screening large regions of the viral ge-
nome in order to detect potential compensatory muta-
tions and new mutations (16).
In Turkey, where about 6500 individuals per year are 
infected with HBV, the virus is characterized by interme-
diate levels (2%–7%) of endemicity (17). Moreover, studies 
conducted in Turkish patients having treated or untreat-
ed CHB infections indicated that HBV drug resistance 
is frequently mediated by rtM204V (YVDD variant) and 
rtM204I (YIDD variant) mutations, and rtM204S (YSDD 
variant) mutations with or without compensatory muta-
tions such as rtV173L and rtL180M are also found, but oc-
cur much less frequently (18-21).
2. Objectives
In the present study, 2 diﬀerent treatment strategies 
were applied for both hepatitis B e antigen (HBeAg)-
positive and HBeAg-negative CHB patients. The aim of 
the study is to determine the patterns and frequency of 
primary and compensatory mutations in patients under-
going long-term NUC treatment using add-on and switch 
therapy strategies.
3. Patients and Methods
3.1. Patients
This study was designed as a retrospective molecular 
study based on diﬀerent rescue strategies implemented 
in the treatment of CHB patients with NUCs. All patients 
were consecutively enrolled. Molecular analysis was per-
formed from March 2007 to November 2010 at the Kocae-
li University Hospital. Patients with CHB were assigned to 
2 groups: the ﬁrst group (n = 88) was treated with NUCs 
using an add-on strategy (adding another drug eﬀective 
against the drug-resistant mutant in patients from the 
Gastroenterology Department) after developing LAM 
resistance; the second group (n = 106) was treated with 
NUCs using a switch strategy (switching to a new antivi-
ral agent after the development of resistance in patients 
from the Infectious Diseases Department). LAM (Zeﬃx, 
100 mg/day; Glaxo Wellcome Laboratories, Middlesex, 
UK), ADV (Hepsera, 10 mg/day; Gilead Sciences Inc., Fos-
ter City, USA), ETV (Baraclude, 0.5 mg/day or 1 mg/day; 
Bristol-Myers Squibb Company, Princeton, USA), and TDF 
(Viread, 245 mg/day; Gilead Sciences Inc., Foster City, USA) 
were the oral anti-HBV drugs used in this study. Clinical 
and laboratory characteristics of patients in each group 
are shown in Table 1. Laboratory results revealed that all 
patients could be categorized as chronic HBV carriers 
according to the clinical practice guidelines of the Euro-
pean Association for the Study of the Liver (EASL) (4). The 
histology activity index, an indicator of liver damage, 
was determined according to Knodell’s classiﬁcation on 
a scale of 0 to 18 (22).
Blood samples were centrifuged immediately after 
collection, and the sera were separated, divided into 
aliquots, and then kept frozen at -20°C until testing. Se-
rological markers of HBV were measured using commer-
cially-available microparticle enzyme immunoassay kits 
(Axsym, Abbott Laboratories, IL, USA, and Elecsys, Roche 
Diagnostics, Mannheim, Germany).837
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3.2. DNA Isolation and Real-Time PCR
HBV DNA was isolated from serum samples with a 
biorobot workstation using magnetic-particle technol-
ogy (NucliSENS-easyMAG, bioMérieux, Boxtel, Holland). 
HBV DNA was detected and quantiﬁed using a commer-
cial real-time PCR assay and platform (Iontek Biyotech-
nology Inc., Istanbul, Turkey; and the iCycler iQ5 detec-
tion system, Bio-Rad Laboratories Inc., California, USA).
3.3. Sequencing of the HBV Polymerase Gene Region
Brieﬂy, a pair of primers was designed (forward: 5’-TC-
GTGGTGGACTTCTCTCAATT-3’ and reverse: 5’-CGTTGA-
CAGACTTTCCAATCAAT-3’) for ampliﬁcation of the HBV 
polymerase region. PCR conditions were 95°C for 15 min, 
followed by 45 cycles consisting of 95°C for 45 s, 56°C for 
45 s, and 72°C for 45 s. The ﬁnal primer concentration was 
0.3 μM, and the HBV amplicon size was 742 bp. All PCR 
products were puriﬁed using the High Pure PCR Product 
Puriﬁcation Kit (Roche Diagnostics GmbH, Mannheim, 
Germany) and directly sequenced on ABI PRISM 310 Ge-
netic Analyzer equipment using the DYEnamic ET Ter-
minator Cycle Sequencing Kit (Amersham Pharmacia 
Biotech Inc., Piscataway, USA). For cycle sequencing, we 
used the following thermal protocol: 35 cycles consisting 
of 95°C for 20 s, 50°C for 25 s, and ﬁnally 60°C for 2 min. 
The reverse primer was used as the sequencing primer 
at a ﬁnal concentration of 0.5 μM. Electropherogram-ob-
tained sequences were assembled using Vector NTI v5.1 
(InforMax, Invitrogen Life Science Software, Frederick, 
MD, USA).
3.4. Determination of HBV Genotype
HBV genotypes were determined using genotyping 
tools from the National Center for Biotechnology Infor-
mation (NCBI, U.S. National Library of Medicine, Bethes-
da, USA, http://www.ncbi.nih.gov/projects/genotyping/
formpage.cgi.) to identify the genotype based on the vi-
ral nucleotide sequences. This genotyping tool works by 
using a BLAST search to compare a query sequence to a 
set of reference sequences for known genotypes (23). The 
Genafor/Arevir geno2pheno drug resistance tool (Cen-
ter of Advanced European Studies and Research, Bonn-
Germany, http://www.geno2pheno.org/.)  was used for 
HBV subgenotyping.
3.5. Determination of Polymerase and Surface Gene 
Mutations
Data accumulated by direct sequencing were analyzed 
either manually or using the geno2pheno tool. The 
Genafor/Arevir geno2pheno drug resistance tool for HBV 
is a database that is speciﬁcally designed for rapid com-
puter-assisted virtual phenotyping of HBV, and accepts 
genome (nucleic acid) sequences as input. This geno-
2pheno program searches for homology between input 
sequences and other sequences already stored in its data-
base, which includes relevant clinical data for drug resis-
tances and surface gene mutations (3). The tool searches 
for HBV drug resistance mutations in the rt domain of 
the polymerase at amino acid positions 80, 169, 173, 180, 
181, 184, 194, 202, 204, 215, 233, 236, and 250. However, we 
also manually analyzed rt amino acid substitutions at 
positions 84, 85, 214, 237, and 238 (6). The overlapping S-
gene segment was evaluated using the geno2pheno tool 
for 5 amino acid substitutions at positions 137, 141, 144, 
145, and 147 and using manual search at positions 121, 135, 
139, 140, 142, 146, 148, 149, 151, 152, 153, 155, 156, and 157 (24).
3.6. Statistical Analysis
Age, HBV DNA load, alanine aminotransferase (ALT) 
levels, and aspartate aminotransferase (AST) levels were 
considered as the numerical values, while gender and 
HBeAg positivity represented the categorical variables. 
The signiﬁcance of diﬀerences between 2 numeric vari-
ables was compared using Mann- Whitney U test. The sig-
niﬁcance of diﬀerences between 2 proportions was mea-
sured using Pearson Chi-square test. P values that were 
≤0.05 were considered statistically signiﬁcant. Statisti-
cal analyses were conducted using SPSS software version 
13.0.0 (SPSS Inc., IL, USA) for Windows.
Demographic data and clinical features for each of the 
study groups are summarized in Table 1. Mutations in 
the HBV polymerase gene known to confer resistance 
to NUCs were found in 122 out of 194 patients (63%). Of 
these 122 patients, 68 (56%) were in the add-on therapy 
group and 54 (45%) were in the switch therapy group. 
Four diﬀerent LAM resistance patterns were identiﬁed in 
84 out of 194 patients (43%): baseline primary mutation 
(rtM204I/V, n = 26), primary mutation with the compen-
satory mutations rtL80I/V (n = 16) or rtL180M (n = 24), 
triple mutant (rtM204I/V + rtV173L + rtL180M or rtA194G, 
n = 12), and the single mutation rtL180M (n = 6). The most 
frequent mutations detected in response to LAM treat-
ment were rtM204I/V and rtL180M (Table 2). LAM-resis-
tance mutations (included ETV resistance mutations) 
were identiﬁed in 48 out of 88 patients (55%) in the add-
on therapy group (median LAM therapy duration, 28.7 
months, with an LAM + ADV combination therapy dura-
tion of 23.3 months) and in 46 out of 106 patients (43%) in 
the switch therapy group (median therapy duration, 24.8 
months). This diﬀerence was not statistically signiﬁcant 
(P > 0.05) (Tables 1 and 2). LdT-resistance patterns were 
identiﬁed in 60 out of 194 patients (31%), and there were 
no signiﬁcant diﬀerences in the frequencies of these mu-
tations between the add-on and switch therapy groups (P 
> 0.05). The observed patterns of LdT resistance included 
baseline primary mutations (rtM204I, n = 24) associated 
with the compensatory mutations rtL80I/V or rtL180M (n 
= 28) and triple mutants (rtM204I + rtV173L + rtL180M or 
rtL80I/V, n = 8; Table 1).
The ADV-associated mutations rtA181T/V, rtN236T, and 
rtA181T + rtN236T were detected in 6, 8, and 2 patients, 
respectively (for a total of 16 out of 194 patients, or 8%). 
Primary ADV-resistance mutations (i.e. N236T) were most 838
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frequently detected. ADV-resistance mutations were 
identiﬁed in 8 out of 88 patients (9%) in the add-on ther-
apy group (median ADV therapy duration, LAM + ADV: 
23.3, ADV + ETV: 19.5 months) and in 8 out of 106 patients 
(7.5%) in the switch group (median therapy duration, 13.1 
months). This diﬀerence was not statistically signiﬁcant 
(P > 0.05; Tables 1 and 2). Single compensatory mutations 
were not detected in the switch therapy group; however, 
rtQ215H/P/S ± rtV214A/P mutations were found in 12 out 
of 88 patients (14%) in the add-on therapy group, and this 
diﬀerence was signiﬁcant (P < 0.01).
The ETV-resistance mutation rtM204I/V + rtL180M + 
rtT184A/I/S or rtS202C was found in 10 out of 194 patients 
(5%). Of these 10 patients, 6 out of 88 (7%) were in the add-
on therapy group (median ETV therapy duration as ADV + 
ETV combination, 19.5 months) and 4 out of 106 (4%) were 
in the switch therapy group (median ETV therapy dura-
tion, 11.4 months). There was no signiﬁcant diﬀerence in 
ETV drug resistance mutations between the 2 groups (P > 
0.05; Tables 1 and 2).
Mutations conferring resistance to TDF were not de-
tected. In 1 patient in the add-on therap    y group, a multi-
drug-resistant HBV strain was detected during combina-
tion therapy with LAM and ADV. Eight patients also had 
changes in the amino acid sequence of the overlapped 
S-gene segment. Two patients in the add-on therapy 
group had sC137G amino acid substitutions (with rtL80M 
+ rtM204I mutations), 2 patients in the switch therapy 
group had sG145R mutations (with rtN236T mutations), 
and 4 patients in the switch therapy group had sD144E 
mutations (1 patient with rtL80M + rtM204V mutations 
and 3 patients with rtQ215S mutations).
Direct sequencing results revealed that all patients had 
HBV genotype D. Subgenotype D1 was identiﬁed as the 
HBV genotype in 74 out of 88 patients (84%) and 82 out 
of 106 patients (77%) in the add-on and switch therapy 
Add-on Strategy, (n = 88) Switch Strategy, (n = 106)
Male, No. (%) 66 (75) 70 (66)
Age, median y (range) 45 (13–68) 38 (16–61)
HBeAg positive, No. (%) 30 (34) 36 (33.9)
ALT b, median U/L (range) 68 (16–537) 84 (12–1082)
AST b, median U/L (range) 61 (14–709) 55 (13–579)
HBV DNA, median log10 IU/mL (range) 4.4 (2.0–6.0) 3.8 (2.0–6.1)
HBV subgenotype D, No. (%)
D1
D2
D3
D4
74 (84)
12 (14)
2 (2)
0 (0)
82 (77)
12 (11)
10 (10)
2 (2)
History of chronic hepatitis B infection
Patients in the immune-tolerant phase
Patients in the immune-reactive phase
HBeAg-negative patients
24
6
58
22
14
70
Biopsy status
Patients with Knodell ﬁbrosis scores
Patients without biopsy
40
48
72
34
Therapy status c
LAM b → LAM + ADV b
ADV → ADV + ETV b
LAM → ADV + ETV
LAM → ADV + TDF b
LAM → ETV
ADV → ETV
74
14
-
-
-
-
-
-
12
10
24
30
Treatment duration,
median mon (range)
LAM
LAM + ADV
ADV
ADV + ETV
ETV
28.7 (3–60)
23.3 (6–48)
-
16 (6–22)
-
24.8 (2–126)
-
13.1 (3–36)
-
11.4 (6–24)
Table 1. Demographic Data and Clinical Features of Patients in Each Study Group a
a Serological markers of all patients were found to be negative for hepatitis C virus and hepatitis D virus.
b Abbreviations: ADV, adefovir dipivoxil; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ETV, entecavir; LAM, lamivudine; TDF, tenofovir 
disoproxil fumarate.
c The combination of NUCs used was selected according to the emergence of drug resistance (primary or compensatory resistance) or clinical and/or 
virological breakthrough.839
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groups, respectively. Of the remaining patients, 12 out of 
88 (14%) and 12 out of 106 (11%) were categorized as sub-
genotype D2, while 2 out of 88 (2%) and 10 out of 106 (10%) 
were categorized as subgenotype D3, in the add-on and 
switch therapy groups, respectively. Subgenotype D4 was 
detected only in 2 out of 106 patients (2%) in the switch 
therapy group (Table 1).
Patients in the add-on and switch therapy groups had 
median HBV viral loads of 4.4 log10 (2.0–6.0) and 3.8log10 
(2.0–6.1) IU/mL, median ALT levels of 68 (16–537) U/L and 
84 (12–1082) U/L, and median AST levels of 61 (14–709) and 
55 (13–579) U/L, respectively (Table 1). Diﬀerences in HBV 
viral load and ALT/AST levels in patients in the add-on and 
switch therapy groups were not signiﬁcant according to 
Mann-Whitney U test (P = 0.310, 0.503, and 0.794, respec-
tively). For patients in the add-on and switch therapy 
groups, the median age was 45 years (range, 13–68) and 
38 years (range, 16–61), respectively, and the number and 
percentage of male patients was 66 (75%) and 70 (66%), 
respectively. Further, HBeAg positivity was detected in 
30 patients (34%) and 36 patients (33.9%), respectively 
(Table 1). Diﬀerences in age, gender, and HBeAg positivity 
were not signiﬁcantly between the 2 groups according to  
Pearson Chi-square test(P = 0.412, P = 0.554, and P = 0.601, 
respectively). Furthermore, demographic data and clini-
cal features, including age, gender, HBeAg positivity, HBV 
DNA load, ALT levels, and AST levels were not found to be 
related to the detection of drug resistance mutations.
Knodell ﬁbrosis scores were assigned to 40 patients in 
the add-on group and 72 patients in the switch group: 19% 
and 15% were scored as 1; 67% and 75% were scored as 2; 11% 
and 10% were scored as 3; and 3% and 0% were scored as 
5, respectively. None of these scores correlated with the 
presence of mutations.
5. Discussion
The long-term use of monotherapy drugs in CHB, and 
LAM in particular, is frequently associated with the de-
velopment of drug resistance. Ideally, antiviral drugs 
used in combination should be carefully chosen to 
have diﬀerent mechanism or sites of action and should 
act in an additive or synergistic fashion (5, 25). Accord-
ing to a recently published study, time-limited add-on 
strategies do not provide beneﬁts over switch strate-
gies with respect to the emergence of ADV-resistant 
mutants in LAM-resistant CHB patients (26). In contrast, 
add-on ADV therapy was found to be more eﬀective and 
longer lasting than ETV as a rescue therapy in patients 
with LAM-resistant mutations who required long-term 
antiviral treatment (27). According to EASL clinical and 
practice guidelines for cases of drug resistance, an ap-
propriate rescue therapy should be initiated with the 
most eﬀective NUCs and with minimal risk of inducing 
multiple drug-resistant strains. Therefore, the only eﬀec-
tive strategy is the addition of a second drug that does 
not display cross-resistance (4). The results of this study 
demonstrated that add-on and switch therapy strate-
Genotypic Resistance Mutation 
(n = 194)
Patients, No. (%) Add-On Strategy
(n = 88)
Switch Strategy
(n = 106)
P value b
No mutations 72 (37%) 20 52 < 0.001
Primary mutations  > 0.05
LAM a 84 (43%) 42 42
rtM204I/V
rtM204I/V + rtL80I/V 
rtM204I/V + rtL180M
rtM204I/V + rtV173L + rtL180M or rtA194G
rtL180M
26
16
24
12
6
14
8
14
4
2
12
8
10
8
4
ETV a 10 (5%) 6 4 > 0.05
rtM204I/V + rtL180M + rtT184A/I/S
rtM204V + rtL180M + rtS202C
8
2
4
2
4
0
ADV a 16 (8%) 8 8 > 0.05
rtA181T/V
rtN236T
rtA181T + rtN236T
6
8
2
4
4
0
2
4
2
LdT a, c 60 (31%) 30 30 > 0.05
rtM204I
rtM204I + rtL180M or rtL80I/V
rtM204I + rtL180M + rtV173L or rtL80I/V
24
28
8
14
12
4
10
16
4
Compensatory mutations 12 (6%) 12 0
rtQ215H/P/S ± rtV214A/P 12 12 0 < 0.01
Table 2. Determination of NUC-Associated Mutational Patterns in Diﬀerent Therapy Strategies
a Abbreviations: ADV, adefovir dipivoxil; ETV, entecavir; LAM, lamivudine; LdT, telbivudine.
b Based on the 2 proportion signiﬁcance tests.
c LdT was not used in either of the therapy strategies. Nevertheless, the patterns and rate of drug resistance to LdT are shown as additional data.840
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gies using NUCs to treat CHB conferred similar major 
drug-resistance patterns at approximately the same fre-
quency, with the exception of compensatory mutations 
such as rtQ215S. Major drug-resistance patterns resulting 
from LAM and LdT treatment occurred more frequently 
than ADV- or ETV-resistance patterns. Resistance to LAM 
and LdT may develop when using these agents in long-
term treatment (median treatment duration with LAM: 
28.7 months in the add-on group and 24.8 months in the 
switch group; Table 1). In fact, studies have shown that 
the frequency of viral resistance progressively increases 
from 10%–27% at the initial diagnosis to 37%–48% by the 
end of the second year of LAM monotherapy (3). In our 
study, the rtM204V mutation was detected as a single 
mutation in only 1 patient under monotherapy. This mu-
tation is usually not detected as a single mutation, but 
instead is usually found in combination with rtL180M 
(5). Replication defects resulting from NUC treatment 
can be partly compensated for by selection for compen-
satory mutations (7, 28). The rtL180M mutation was the 
most common compensatory mutation in our study. 
In vitro studies have demonstrated that this mutation 
alone is insuﬃcient to result in LAM resistance; how-
ever, this mutation augments both viral replication and 
LAM resistance in the context of rtM204I/V mutations. 
The rtV173L HBV mutation occurs in 9% of LAM-resistant 
patients (5) and serves to further increase the replica-
tion capacity of poorly replicating LAM-resistant HBV 
(2). Mutation at codon rtL80I/V may also be an alterna-
tive compensatory mutation to rtL180M in HBV genomes 
encoding the rtM204I mutation, and this mutation may 
act in a manner similar to rtQ215S. In the current study, 
mutations at rtQ215S were only observed in the add-on 
therapy group in 12 patients (14%), while previous studies 
have described the rtQ215S mutation as a polymorphism 
that is detected in ~12% of patients treated with LAM (5). 
Substitutions at rtQ215 also occur during ADV therapy 
(6). However, Olyaee et al. demonstrated no association 
between rtQ215 mutations and clinical complications 
in patients infected with HBV genotype D (29). Accord-
ingly, in our previously published report, we found that 
rtQ215A/H/P/S substitutions could be detected as natural-
ly occurring mutations in treatment-naïve patients with 
CHB (30). Furthermore, rtQ215H/P/S substitutions occur 
as dominant compensatory mutations in treatment-
naïve hemodialysis patients infected with HBV genotype 
D (unpublished data). However, in vitro studies suggest 
that rtQ215 substitutions impair neither viral replication 
eﬃciency nor susceptibility to LAM or ADV (29). LdT, an-
other nucleoside analog, also selects for mutations in the 
YMDD motif, similar to mutations conferring resistance 
to LAM, and is not expected to be eﬀective in LAM-resis-
tant patients. Resistance to LdT also begins to emerge in 
the ﬁrst year of treatment and progressively increases 
during the second year of therapy (3). LdT was not used 
in either therapy strategy implemented in this study. 
Nevertheless, we included the frequency and patterns of 
LdT drug resistance in Table 2, according to EASL clinical 
and practice guidelines (4).
The rtA181T HBV mutation is a major mutation pattern 
associated with LAM resistance, but selected for during 
ADV treatment and during the development of resis-
tance to combination (ADV + LAM) therapy in the absence 
of mutations at rtM204I/V (5). In this study, rtA181T muta-
tions were detected in 6 patients who did not also carry 
the rtM204I/V mutation. ADV drug resistance detected in 
this study was found to be associated with mutations at 
rtN236T and rtA181T/V. Further, rtQ215S and rtV214A mu-
tations were compensatory mutations arising from ADV 
treatment (10). However, while the rtN236T substitution 
does not signiﬁcantly aﬀect sensitivity to LAM, rtA181T/V 
and rtQ215S/rtV214A mutations confer partial cross-resis-
tance to LAM (31).
Resistance to ETV is associated with 2 diﬀerent mu-
tation proﬁles, both of which include LAM-resistance 
mutations (5, 9, 32). High levels of ETV resistance re-
sulted from dual rtM250V and rtI169T mutations, and 
we detected another proﬁle, the rtM204I/V + rtL180M + 
rtT184A/I/S or rtS202C triple mutation, as an ETV-resistant 
mutation in both NUC therapy strategies. On the other 
hand, 24 patients receiving LAM treatment in the switch 
therapy group were switched to ETV therapy at 1 mg daily 
(Table 1), and while these patients had no LAM-resistance 
mutations, they were refractory to LAM therapy. In this 
group of LAM-refractory patients, the emergence of ETV 
resistance occurred more frequently than was the case 
with NUC treatment-naïve patients (33). ETV and TDF are 
both potent HBV inhibitors and have a high barrier to re-
sistance. Thus, they can be conﬁdently used as ﬁrst-line 
monotherapies (4).
HBV strains that are resistant to at least 2 anti-HBV 
agents from diﬀerent NUC subclasses without cross-
resistance proﬁles are deﬁned as multidrug-resistant 
strains (3). These multidrug-resistant strains are more 
likely to develop additional mutations with sequential 
therapy (34-36). In the current study, we found 1 patient 
with dual ADV (rtN236T + rtQ215H) and LAM (rtM204V + 
rtL180M + rtV173L) resistance, detected in diﬀerent serum 
samples from the same patient. Recently, the emergence 
of the ﬁrst multidrug-resistant HBV strain arising from 
sequential oral anti-HBV therapies was documented (35). 
Nevertheless, there is limited in vivo data demonstrating 
resistance to multiple NUCs (3).
Because of overlapping open reading frames of the HBV 
polymerase and the HBsAg, drug resistant mutations 
in the HBV polymerase can have a direct impact on the 
nature of the HBsAg and its function (28, 37). Mutations 
in and around the major neutralization domain of HBV, 
known as the ‘a’ determinant, may result in decreased 
aﬃnity of the HBsAg to anti-HBs and cause diagnostic 
problems and/or failure to prevent infections by vaccina-
tion or HB immunoglobulin (7, 38). Studies have shown 
that LAM-resistant HBV (harboring the rtV173L + rtL180M 
+ rtM204V triple mutation) has signiﬁcantly reduced an-841
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ti-HBs binding capacity due to changes in the HBsAg (37). 
Both our previous studies and the present study demon-
strate that the overlapping S-gene segment (sC137, sG145, 
and sD144) was aﬀected by genotypic resistance associ-
ated with NUC treatment (39). Mutant sG145R is the most 
frequently reported modiﬁcation and is a known vaccine 
escape mutant (7, 40). It appears to seriously impair the 
performance of many commercial tests and is respon-
sible for false-negative results (37). However, the Axsym 
and Elecsys tests used in this study successfully detected 
this mutation.
The occurrence of NUC-resistant HBV variants can com-
monly be detected by direct sequencing of HBV DNA (41). 
This method is required for the identiﬁcation of any 
novel mutation  within the target gene (1, 12). Further-
more, while direct sequencing is a time-consuming task 
when dealing with a large numbers of clinical samples, 
it is suitable for the screening of a large region of the vi-
ral genome (in this case, the HBV polymerase gene). The 
geno2pheno program is a useful tool that facilitates a 
simple and rapid analysis of mutations associated with 
NUC resistance in large regions of the HBV genome. In 
this study, we used both manual analysis of sequence 
mutations and the geno2pheno drug resistance tool. We 
found similar results when analyzing our data manually 
and using the geno2pheno program, with the exception 
of 1 patient with ETV drug resistance (rtM204V + rtL180M 
+ rtT184S). DNA chromatograms obtained from this pa-
tient show 2 peaks for the same nucleotide signal (both 
a wild- and mutant-type peak). Because the base c    alling 
algorithm used by drug resistance tools selects the most 
prominent signal to deﬁne each nucleotide, both manu-
al analysis and the use of drug resistance tools, such as 
geno2pheno, should be used together to interpret drug 
resistance mutations.
Several studies have shown that HBV genotype D rep-
resents almost all isolates from the Turkish HBV patient 
population (33, 39, 42, 43). However, we recently docu-
mented a case of HBV genotype A in Turkish patient (44). 
The present study demonstrated that HBV genotype D is 
still dominant among Turkish CHB-infected patients. Be-
cause of the dominance of genotype D, it is diﬃcult to 
evaluate NUC resistance in relation to the diﬀerent geno-
types of HBV. A limited number of reports have demon-
strated the relationship between HBV genotype and the 
response to antiviral therapy with LAM (15). Zollner et al. 
reported that the mutational pattern during the selec-
tion of LAM-resistant HBV strains diﬀers between geno-
types A and D. However, EASL clinical practice guidelines 
have not yet supported any relationship between the 
HBV genotype and response to NUC therapy (4). To date, 
there is little data describing the subgenotyping of HBV 
in Turkish patients. In the present study, HBV pol gene 
sequences isolated from Turkish patients revealed that 
subgenotype D1 constitutes the majority of genotype D 
circulating in Turkey. We also demonstrated the pres-
ence of subgenotypes D2, D3, and D4; however, based on 
pol gene sequencing, HBV subgenotype D1 was predomi-
nant (84%) and subgenotypes D2, D3, and D4 were found 
in only 10%, 5%, and 0.2% of Turkish patients with CHB (n 
= 442), respectively (45). In contrast, other groups have 
shown that subgenotype D2 is the predominant HBV sub-
genotype in Turkish patients (46-48). While both these 
studies use pre-S gene ampliﬁcation along with restric-
tion fragment length polymorphism techniques, the 
discrepancies in the reported results are probably due to 
diﬀerences in methodology.
In conclusion, CHB is a disease that can develop pro-
gressive resistance to NUCs by mutations in the HBV 
polymerase gene. Therefore, it is necessary to use eﬀec-
tive therapeutic strategies to manage drug resistance. 
However, we did not detect a signiﬁcant diﬀerence in the 
emergence of major drug resistance patterns and their 
frequencies when add-on and switch strategies were 
implemented. These ﬁndings may prove to be useful in 
the management of rescue strategies in LAM-resistant 
patients.
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